Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors

Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.

Publication Details

Journal
Cancer Discovery
Published
2026-11-12
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0106
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors

Cancer Discovery
CAR-T cell therapy research
article

Anti-CAR Antibodies May Undermine Cell Therapy in Brain Tumors

article en

Abstract

Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.

Cancer Discovery
Good health and well-being
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon